Mustang Bio Analyst Ratings
Mustang Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 520.35% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 06/16/2023 | 396.28% | BTIG | $4 → $20 | Maintains | Buy |
| 06/16/2023 | 520.35% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/15/2023 | 73.7% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 03/30/2023 | 73.7% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 11/16/2022 | -0.74% | BTIG | $8 → $4 | Maintains | Buy |
| 01/24/2022 | 48.88% | B. Riley Securities | $13 → $6 | Maintains | Buy |
| 05/18/2021 | 172.95% | BTIG | → $11 | Initiates Coverage On | → Buy |
| 12/23/2020 | 222.58% | B. Riley FBR | → $13 | Reinstates | → Buy |
| 10/02/2020 | 123.33% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 05/12/2020 | 222.58% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 11/20/2019 | 73.7% | Cantor Fitzgerald | → $7 | Assumes | → Overweight |
| 08/13/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 08/13/2019 | 73.7% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 06/21/2019 | 73.7% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月15日 | 520.35% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 06/16/2023 | 396.28% | BTIG | $4→$20 | 維護 | 買 |
| 06/16/2023 | 520.35% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 2023年05月15日 | 73.7% | HC Wainwright公司 | →$7 | 重申 | 購買→購買 |
| 03/30/2023 | 73.7% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 2022年11月16日 | -0.74% | BTIG | $8→$4 | 維護 | 買 |
| 01/24/2022 | 48.88% | B.萊利證券 | $13→$6 | 維護 | 買 |
| 2021/05/18 | 172.95% | BTIG | →$11 | 開始承保 | →購買 |
| 12/23/2020 | 222.58% | B.萊利FBR | →$13 | 恢復 | →購買 |
| 10/02/2020 | 123.33% | B.萊利證券 | →$9 | 開始承保 | →購買 |
| 2020/05/12 | 222.58% | 奧本海默 | $15→$13 | 維護 | 跑贏大盤 |
| 2019年11月20日 | 73.7% | 康託·菲茨傑拉德 | →$7 | 假設 | →超重 |
| 2019年08月13日 | - | HC Wainwright公司 | 開始承保 | →購買 | |
| 2019年08月13日 | 73.7% | HC Wainwright公司 | →$7 | 開始承保 | →購買 |
| 2019年06月21日 | 73.7% | 康託·菲茨傑拉德 | →$7 | 開始承保 | →超重 |
What is the target price for Mustang Bio (MBIO)?
野馬生物(MBio)的目標價是多少？
The latest price target for Mustang Bio (NASDAQ: MBIO) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $25.00 expecting MBIO to rise to within 12 months (a possible 520.35% upside). 6 analyst firms have reported ratings in the last year.
野馬生物(納斯達克代碼：MBIO)的最新目標價是由HC Wainwright&Co.於2023年8月15日報道的。這家分析公司將目標價定為25美元，預計mBio將在12個月內上漲(可能上漲520.35)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Mustang Bio (MBIO)?
野馬生物(Mustang Bio)最新的分析師評級是多少？
The latest analyst rating for Mustang Bio (NASDAQ: MBIO) was provided by HC Wainwright & Co., and Mustang Bio reiterated their buy rating.
野馬生物(納斯達克代碼：MBIO)的最新分析師評級由HC Wainwright&Co.提供，野馬生物重申其買入評級。
When is the next analyst rating going to be posted or updated for Mustang Bio (MBIO)?
野馬生物(Mustang Bio)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mustang Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mustang Bio was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與野馬生物的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。野馬生物的最後一次評級是在2023年8月15日提交的，所以你應該預計下一次評級將在2024年8月15日左右的某個時候公佈。
Is the Analyst Rating Mustang Bio (MBIO) correct?
分析師對野馬生物(Mustang Bio)的評級正確嗎？
While ratings are subjective and will change, the latest Mustang Bio (MBIO) rating was a reiterated with a price target of $0.00 to $25.00. The current price Mustang Bio (MBIO) is trading at is $4.03, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的野馬生物(Mustang Bio)評級被重申，目標價在0.00美元至25.00美元之間。野馬生物(Mustang Bio)目前的交易價格為4.03美元，在分析師的預測區間內。